• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.16% Nasdaq Down0.13%

    Exelixis, Inc. (EXEL)

    -NasdaqGS
    3.34 Down 0.10(2.91%) Jun 2, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Exelixis, Inc.
    210 East Grand Avenue
    South San Francisco, CA 94080
    United States - Map
    Phone: 650-837-7000
    Fax: 650-837-8300
    Website: http://www.exelixis.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:85

    Business Summary 

    Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer. It is also evaluating cabozantinib in various development programs comprising approximately 45 clinical trials, including 2 ongoing phase 3 pivotal trials focusing on metastatic renal cell carcinoma (mRCC) and advanced hepatocellular carcinoma (HCC). In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase 3 pivotal trial evaluating in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Exelixis, Inc.

    Corporate Governance 
    Exelixis, Inc.’s ISS Governance QuickScore as of May 1, 2015 is 6. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 5; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Stelios Papadopoulos Ph.D., 67
    Chairman and Member of Audit Committee
    58.00KN/A
    Dr. Michael M. Morrissey Ph.D., 54
    Chief Exec. Officer, Pres and Director
    762.00K0.00
    Ms. Deborah Burke , 59
    Chief Financial Officer, Sr. VP and Controller
    326.00K0.00
    Mr. Peter Lamb Ph.D., 54
    Chief Scientific Officer and Exec. VP of Discovery Research
    414.00K0.00
    Mr. Jeffrey J. Hessekiel J.D., 46
    Exec. VP, Gen. Counsel and Sec.
    380.00KN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders